ANXA2 and endometrial carcinoma: When the cases of endometrial carcinoma were further divided into high (++/+++) and low ANXA2 expression groups (−/+), the high expression rate of ANXA2 in stage III–IV endometrial carcinoma patients was 91.7 % (22/24), which was significantly higher than stage I–II patients (55.0 % [33/60], p < 0.05) (Table 2).